ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
A single arm, phase 2 Study of ARX788 in HER2-positive metastatic breast cancer patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.
Breast Cancer
DRUG: ARX788
Objective remission rate (ORR), The proportion of patients who have a CR or PR, as determined by the Investigator at local site per RECIST 1.1., Until progression, assessed up to approximately 24 months
Disease control rate (DCR), The proportion of patients who have a CR or PR or SD, as determined by the Investigator at local site per RECIST 1.1., Baseline through end of study, assessed up to 24 months]|Duration of relief (DOR), Time from the date of first documented response until the date of documented progression or death in the absence of disease progression, Until progression, assessed up to approximately 24 months|Progression-free survival (PFS), Time to progression as assessed by the Investigator at local site per RECIST 1.1, or death due to any cause., Until progression or death, assessed up to approximately 36 months]|Overall survival (OS), Time to death due to any cause, Until death, assessed up to approximately 50 months|The number of subjects experiencing adverse event TEAEs, Occurrence of AEs according to CTCAE v5.0, Up to follow-up period, approximately 50 months
A single arm, phase 2 Study of ARX788 in HER2-positive metastatic breast cancer patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.